Literature DB >> 3040247

Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial.

R E Drasga, S D Williams, L H Einhorn, R Birch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3040247

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  2 in total

1.  Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.

Authors:  B A Murphy; R J Motzer; G J Bosl
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

2.  Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

Authors:  C Kollmannsberger; O Rick; H Klaproth; T Kubin; H G Sayer; M Hentrich; M Welslau; F Mayer; M Kuczyk; C Spott; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.